The meeting will start promptly at 10:00 and is expected to finish at approximately 15:00
Please note that this agenda is subject to change before the meeting.
The Committee for Medicinal Products for Human Use (at the European Medicines Agency) has not yet given its regulatory opinion for cemiplimab for treating cutaneous squamous cell carcinoma and as a consequence this discussion will take place in a part 2 session (part 2 sessions are closed to public observers).
To print an agenda, please right click and select 'Print' from the menu.
The next meeting will take place on Thursday 16 May 2019 at 10am,, London venue (tbc)
Please note all timings are approximate.